Virtual oncology research—different models and lessons learned

P. Ranganathan\textsuperscript{a} and C.S. Pramesh\textsuperscript{b}

Purpose of review
The COVID-19 pandemic posed several challenges to cancer research including halting of trials, reduced recruitment and protocol violations related to inflexible processes followed in clinical trials. Researchers adopted innovative measures to mitigate these problems and continue studies without compromising their quality. This review collates these adaptations that could well continue after the pandemic.

Recent findings
The COVID-19 pandemic forced researchers globally to adopt innovative measures to overcome the challenges of the pandemic. These included protocol amendments to adjust to the pandemic and travel restrictions, and increased use of digital technologies. ‘Virtual’ clinical trials were conducted increasingly with adaptations in ethics and regulatory approvals, patient recruitment and consenting, study interventions and delivery of study medications, trial assessments, and monitoring. Many of these adaptations are safe and feasible, without compromising study quality and data integrity. Although these may not be universally applicable in all types of research, they bring many benefits including more diverse patient participation, less burden on patients for study procedures and reduced resources to conduct trials.

Summary
The COVID-19 pandemic has affected cancer research adversely; however, learnings from the pandemic and adaptations from researchers are likely to improve the efficiency of clinical research beyond the pandemic.

Keywords
cancer research, COVID-19, pandemic, virtual clinical trials

INTRODUCTION
The COVID-19 pandemic has had a widespread impact on health and healthcare in many ways. In addition to the morbidity and mortality of the infection itself, the focus on COVID-19 has diverted attention and resources from other illnesses, especially noncommunicable diseases. Cancer care has undoubtedly been affected adversely; however, a less recognised effect has been the impact on cancer research. Recruitment into trials and maintaining due process during the conduct of studies was particularly challenging. However, the pandemic resulted in an exponential use of digital technology to replace various in-person processes, and this extended to the conduct of clinical research as well. Even prior to the pandemic, several clinical trials had some components that were conducted remotely; the restrictions during the pandemic have led to increasing acknowledgement of the utility of digital technology in the conduct of clinical trials – the so called ‘virtual’ clinical trials.

Virtual clinical trials (also known as remote, decentralised, digital, siteless or direct-to-participant trials) refer to digitally empowered clinical trials that utilise technology at every stage of the trial process to bring trials closer to the participant. In this review, we look at the components of virtual clinical trials, and their benefits and disadvantages. To identify relevant articles on this topic, we searched PubMed using a combination of the terms ‘virtual’ AND ‘oncology’ OR ‘cancer’ AND ‘clinical trial’ OR ‘research’. We did not restrict the search to a particular time period or language.
Clinical research in general including cancer research has the potential to be far more efficient than it is currently.

Several aspects of clinical research can be conducted virtually using digital and other tools that can diversify patient participation, improve study efficiency, and make research patient-centric rather than site-centric.

These learnings and adoptions from the pandemic could well be extended to normal times without compromising study quality or data integrity.

THE IMPACT OF COVID-19 ON CANCER RESEARCH

The COVID-19 pandemic affected cancer research in several ways [1,2]. Travel restrictions during the pandemic and the fear of acquiring COVID-19 resulted in decreased hospital visits with slow recruitment on trials and protocol violations related to study interventions and assessments. Oncology research protocols were adapted or modified to minimise immunosuppression which could increase the risk of acquiring COVID-19, or to reduce the frequency of assessment and follow-up. Disruptions of pharmaceutical supply chains resulted in nonavailability of investigational products. There were staff shortages due to deployment to clinical areas or due to infection or quarantine. Laboratories were burdened with the need for testing for COVID-19, putting research investigations on the backburner. Funding was diverted from research to essential areas. The overall impact of these measures was a substantial decrease in new oncology trials, decreased patient accrual on existing trials, and temporary or permanent cessation of several trials, leading to delays in the development of therapies in oncology [2].

Based on data from clinicaltrials.gov, Upadhyay and colleagues reported considerable decreases in patient enrolment in oncology clinical trials during the early part of the pandemic [3]. Out of 36 oncology researchers in the USA and Europe, less than 20% were continuing to enrol patients on trials. In a follow-up study [4], they found that overall, between March 2020 and April 2021, 386 oncology trials were halted. The peak stoppage occurred in June 2020 followed by a slow recovery. Even a year after this (mid-2021), almost 30% of these trials were still on hold or had been withdrawn or terminated. Data from 64 National Cancer Institute (NCI) designated cancer centres, showed a precipitous fall in enrollment in the early stages of the pandemic which had not recovered to pre-pandemic levels even in mid-2021 [5]. There was a 60% decrease in the number of launches of oncology clinical trials of drugs and biological therapies on a commercial clinical trial platform during the pandemic [6]. Similarly, many other centres have reported declines in research activities due to COVID-19 [7–11].

Several oncology societies and organisations such as the US-FDA, NCI, European Medicines Agency (EMA), and the United Kingdom Medicines and Healthcare products Regulatory Agency issued guidelines to navigate the challenges of conducting oncology research during the pandemic [12–16]. These guidelines focus on a digitally enhanced, decentralised and participant-centric approach.

CLINICAL TRIALS IN ONCOLOGY

Conventional clinical trials in oncology are extremely resource-intensive. They are site-centric i.e., centred around medical facilities like the hospital or clinic, which are usually academic centres in urban settings and are not easily accessible to patients from remote areas, or those who have difficulty in travelling to the site. Oncology protocols also tend to be complex, necessitating frequent visits by participants for initial screening, delivery of study interventions, and safety and outcome assessments. For most trials, monitoring to ensure data integrity and participant safety involves multiple site visits by monitoring staff. All of these require investment in terms of infrastructure, human resource and funding.

THE ‘VIRTUAL’ CLINICAL TRIAL

In any clinical trial, all or some aspects may be carried out remotely - defined as ‘virtual’ or ‘hybrid’ clinical trials. It is now clear that the advantages offered by the virtual or hybrid approach will be useful even in the postpandemic period. Several authors have described the key features of virtual clinical trials [17**,18**,19*,20**–22**,23*,24*].

ETHICS AND REGULATORY APPROVALS

The pandemic resulted in several ethics committees adopting procedures for electronic submission of documents by researchers, and virtual meetings to approve projects. Regulatory agencies also switched to acceptance of electronic submissions. Many countries laid out guidelines for the expedited approval of research projects especially those related to the diagnosis and management of COVID-19. Some centres initiated the process of single committee approval for multicentric projects, hastening the trial approval process [25,26]. Aided by developing
technology, these processes could continue well beyond the pandemic to non-COVID-19 research as well.

**PARTICIPANT RECRUITMENT**

Patient recruitment is a major hurdle in clinical research and it has been estimated that less than 10% of patients with cancer are part of a clinical research study even in normal times [18**,27]. The use of digital technology can help to improve recruitment rates [23*]. For example, the use of artificial intelligence tools can help to match patients to appropriate ongoing clinical trials and to identify rare groups of patients with uncommon cancers [18**,28]. Screening tests are carried out prior to patient enrollment to determine if participants meet the eligibility criteria and can safely receive the study interventions. The screening of patients for eligibility for participation could be carried out virtually by reviewing essential clinical parameters and investigations through digital techniques [21**]. For this, it is preferable to restrict screening tests to those which are absolutely essential to ensure participant safety and study validity.

**PARTICIPANT ENROLLMENT**

Technology can also be used to streamline the enrollment process, including patient counseling and consenting. The process of informed consent for participation in a trial usually includes several site visits involving dissemination of information to the participant, counselling and clarification of queries and finally the signature process. In a remote consenting technique, blank consent forms are mailed to participants, followed by a virtual discussion and forms are signed electronically. A reduction in the number of visits needed for enrollment will allow inclusion of populations that are traditionally under-represented in clinical trials e.g., those living in remote areas or those with mobility issues [18**].

**STUDY INTERVENTIONS**

Trial participants make several site visits to receive study interventions. In a virtual clinical trial, various modalities could be used to deliver study medications to the participant [19*,23*]. These include personal delivery of study drugs to participants by research staff, use of medical delivery services, medication pick-up from specified sites or shipping of study medications through the mail. For medications which need to be delivered parenterally, tie-ups with local providers or home-based care providers may be needed. During these processes, it is essential to ensure that there is accountability for the investigational product, that storage and delivery requirements are adhered to, and that blinding is maintained [22*].

**CARE OF RESEARCH PARTICIPANTS**

Continued medical care of participants during the trial is important to monitor compliance to trial interventions, ensure the safety of participants and allow early identification of adverse events. In conventional clinical trials, this involves repeated site visits for the assessment of safety and efficacy outcomes. In a virtual clinical trial, the care of trial participants could be transferred to local providers to decrease travel requirements. Digital technology using telemedicine or video calls can also be used to allow investigators to conduct remote consultations with participants.

**STUDY ASSESSMENTS**

In a virtual clinical trial, it is essential to choose appropriate study outcomes. Since collection of samples may be difficult, researchers should also consider converting outcomes to those that can be measured at home. Various approaches have been described to allow remote study assessments [20**]. Participants could use home-based non-invasive devices (e.g., pulse oximeter, glucometer, fitness bands) to provide data on parameters such as vital signs, physical activity, or sleep patterns. In addition to providing real-time data, these methods allow early identification of adverse events compared to interval-based assessments [18**]. Participants could also report symptoms using self-administered, telephonic or web-based questionnaires. If clinical examination is needed, coordination with local healthcare providers can allow in-person assessments, and researchers could access electronic health records to obtain the relevant information.

Study assessments requiring laboratory tests or imaging techniques may pose a problem. Again, local facilities may be used for these assessments. Alternatively, participants could be instructed to perform simple home tests (e.g., finger-prick method or urine samples) or home visits by laboratory personnel could be arranged. Depending on the complexity of the test required and the resources available locally, samples could either be analysed at local labs or shipped to a central laboratory for testing. For imaging modalities, digital images could be shared to a central facility for review by a radiologist.
MONITORING OF CLINICAL TRIALS

Periodic monitoring of ongoing clinical trials helps to protect participant safety and data integrity, and ensures that the trial is conducted in keeping with the study protocol. Typically, in-person study monitoring is conducted at each trial site by a monitoring team. In virtual trials, monitoring can be conducted remotely using digital tools to access trial-related documents. This can be done in many ways: e.g., sharing scanned copies of trial documents via e-mail, sharing computer screen via a video-conferencing application or providing remote access to electronic medical records. A large part of trial costs is attributed to on-site monitoring, which for some large global clinical trials could be up to 60% of all trial costs [29]. However, there is no evidence to support this approach, and none of the randomised trials comparing intensive with less intensive monitoring have shown clinically relevant treatment outcomes [29]. We strongly advocate an approach of remote monitoring and risk-based monitoring even after the pandemic.

Table 1 lists the components of a clinical trial and the modifications that can be made to suit the virtual format.

EXAMPLES OF VIRTUAL TRIALS

The TOPAZ trial was a home-based trial evaluating the efficacy of zolendronic acid in preventing fractures in elderly patients with Parkinson's disease [30]. The virtual format of this trial with recruitment via support groups and websites, online consenting, diagnosis through telemedicine, administration of home-based therapy via research nurses, and assessment of endpoints by surveying electronic health records or follow-up via mail, e-mail or phone every 6 months made the trial feasible in a population which might otherwise have not been able to participate in a site-centric trial due to mobility issues.

Oxman studied the effect of Valerian for insomnia in a web-based randomised trial [31]. Participants were recruited through a weekly nationally televised health program and enrollment and data collection was carried out via the internet. Study...
medications were mailed to participants and outcomes were assessed via a self-recorded diary.

ADVANTAGES OF VIRTUAL CLINICAL TRIALS

Virtual clinical trials offer several benefits for oncology (and other biomedical) research. They expand the pool of patients who can participate in a trial and enhance participant enrolment [18**]. Since trial processes are carried out at or near the participants’ location, the burden on participants is reduced, leading to fewer drop-outs and better retention. This also ensures better compliance with the protocol, with fewer violations and improved data quality. Virtual trials consume less resources in terms of staffing, infrastructure and funding [32]. Real-time monitoring of outcomes may allow the earlier detection of adverse events [18**]. The inclusion of a diverse pool of participants, along with patient-centred study processes provides real-world data on the efficacy of an intervention compared to the results of a site-centric clinical trial with its tightly controlled operations [33].

CAVEATS WITH VIRTUAL CLINICAL TRIALS

However, virtual trials also pose several challenges. These trials may not be suitable in all settings [22**]. For example, early phase trials that need pharmacokinetic monitoring or studies involving complex interventions which may be performed only at specialised centres need to be carried out at specific sites. Similarly, these trial formats may work better with oral rather than parenteral medications and for interventions whose safety has already been established but are now being considered for a new indication. Participants with acute health conditions like trauma, stroke or myocardial infarction, or those with cognitive impairment may not be able to comply with the requirements of a virtual trial. Virtual trials are heavily technology-dependent; the digital divide means that certain populations who have poor access to, or are unable to use the required technology may still be under-represented in such trials. Regulatory requirements related to research are constantly evolving and while many countries have eased up research regulations during the pandemic, these vary between countries and may not apply to the post-pandemic situation. Electronic consent, data capture and data sharing require specialised encrypted secure web applications. There are concerns about the privacy of participants and the security and confidentiality of data. The delivery of study drugs to the participant without site visits increases the complexity of supply chain logistics. Standards of drug storage, handling and administration may be variable leading to inconsistent drug delivery and effect. Quality control and acceptable limits for differences in drug delivery need to be specified. For some interventions such as cognitive therapy or behavioural interventions, remote delivery may not be as impactful as when carried out in person [20**]. In addition, some interventions may be risky when carried out remotely by unsupervised participants e.g., walk tests in elderly patients. For laboratory and imaging assessments carried out at local facilities, reference values may be different [22**]. Care should be taken to include only accredited facilities with the incorporation of quality control measures at regular intervals. If adverse events occur, they need to be managed at the local level. Though remote monitoring has been accepted by many regulatory authorities, some of them mandate reverification of documents in a subsequent in-person visit. Switching to the virtual format requires additional training of all stakeholders in the research process. Finally, there may be specific insurance and indemnity requirements that need to be accounted for.

CONCLUSION

Virtual clinical trials are an excellent and feasible alternative to conventional clinical trials in certain situations. They are patient rather than site-centric and allow decentralisation of trial-related processes. They decrease the complexity of trials, consume less resources, reduce costs, shorten timelines and can potentially improve participant engagement, recruitment and retention. However, they may not be suitable in all settings and need to be considered for specific types of research questions, study designs and patient populations.

Acknowledgements

None.

Financial support and sponsorship

None.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

* of special interest
** of outstanding interest

1. Fox L, Beyer K, Ramnant E, et al. Impact of the COVID-19 pandemic on cancer researchers in 2020: a qualitative study of events to inform mitigation strategies. Front Public Health 2021; 9:741223.
The post covid new patterns of practice

2. Williams PA, Zaidi SK, Sengupta R. ACR report on the impact of COVID-19 on cancer research and patient care. Clin Cancer Res 2022; 28:609–610.

3. Upadhyaya S, Yu JX, Oliva C, et al. Impact of COVID-19 on oncology clinical trials. Nat Rev Drug Discov 2020; 19:376–377.

4. Upadhyaya S, Yu JX, Hodge J, Campbell J. COVID-19 impact on oncology clinical trials: a 1-year analysis. Nat Rev Drug Discov 2021; 20:415.

5. Prindiville SA, Sarosy GA, Loose D, et al. Patterns of enrollment in cancer treatment trials during the COVID-19 pandemic at National Cancer Institute-Designated Cancer Centers. Cancer J 2022; 32:111–117.

6. Lamont EB, Diamond SS, Katriel RS, et al. Trends in oncology clinical trials launched before and during the COVID-19 pandemic. JAMA Netw Open 2021; 4:e2038353.

7. Ranganathan P, Sengar M, Chinnaswamy G, et al. National Cancer Grid of India. Impact of COVID-19 on cancer care in India: a cohort study. Lancet Oncol 2021; 22:970–976.

8. Bakouzy Z, Labaki C, Bhalla S, et al. Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study. Ann Oncol 2022; S0020-7345000761-X.

9. O’Reilly S, Murphy V, Mulroe E, et al. The SARS-CoV-2 pandemic and cancer trials Ireland: impact, resolution and legacy. Cancers (Basel) 2022; 14:2247.

10. Mulliro R, Fernández-Deaza G, Zulagua M, et al. Cancer research in the time of COVID-19: A Colombian Narrative. Front Public Health 2022; 9:750755.

11. Sundquist S, Kato D, Xu RY, et al. “Guidance for Industry, Investigators, and Institutional Review Boards.” Center for Drug Evaluation and Research. U.S. Food and Drug Administration, August 2021. Available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medicinal-products-during-covid-19-public-health-emergency. Last accessed on 21st June 2022.

12. “Guidance for Clinical Trial Activities Affected by the Novel Coronavirus.” Cancer Therapy Evaluation Program (CTEP), National Cancer Institute. Division of Cancer Treatment and Diagnosis, March 13, 2020. Available at https://ctep.cancer.gov/investigatorResources/corona_virus_guidance.htm. Last accessed on 21st June 2022.

13. “Interim Guidance for How to Manage Clinical Trials during the COVID-19 Pandemic.” European Medicines Agency, June 19, 2020. Available at https://www.ema.europa.eu/en/news/guidance-sponsors-how-manage-clini-cal-trials-during-covid-19-pandemic. Last accessed on 21st June 2022.

14. “Interim Guidance for Clinical Trial Activities Affected by the Novel Coronavirus.” Cancer Therapy Evaluation Program (CTEP), National Cancer Institute. Division of Cancer Treatment and Diagnosis, March 23, 2020. Available at https://ctep.cancer.gov/investigatorResources/corona_virus_-guidance.htm. Last accessed on 21st June 2022.

15. “Guidance to Sponsors on How to Manage Clinical Trials during COVID-19.” European Medicines Agency, June 19, 2020. Available at https://www.ema.europa.eu/en/news/guidance-sponsors-how-manage-clinical-trials-during-covid-19-pandemic. Last accessed on 21st June 2022.

16. “Managing Clinical Trials during Coronavirus (COVID-19).” Medicines and Healthcare products Regulatory Agency, March 19, 2020 (updated 16 Nov 2021). Available at https://www.gov.uk/guidance/managing-clinical-trials-during-coronavirus-covid-19. Last accessed on 21st June 2022.

17. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Drug Discovery, Development, and Translation. Virtual Clinical Trials: Challenges and Opportunities: Proceedings of a Workshop. Shore C, Khandekar E, Alper J, editors. Washington (DC): National Academies Press (US); 2019 Jul 23.

This report outlines summaries the proceedings of a workshop convened to examine the current status of clinical trials and the emerging role of virtual clinical trials. The authors also discuss real-life examples of virtual clinical trials and the challenges faced in the conduct of these trials.

18. Kadakia KT, Asaad M, Adilahia E, et al. Virtual clinical trials in oncology—overview, challenges, policy considerations, and future directions. JCO Clin Cancer Inform 2021; 5:421–425.

This review article provides an overview of the conduct of virtual clinical trials in oncology and looks at considerations for the various stake-holders in the research process – i.e., participants, healthcare providers and regulators.

19. Kadakia KT, Halpeirn DM. Offfide AC 2nd. Operationalizing virtual trials in oncology—from aspiration to action. JCO Clin Cancer Inform 2021; 5:953–957.

20. COVID-19 has led to the digitalization and decentralization of medical care and research. This article discusses various ways in which clinical research in oncology can be implemented using virtual methods.

21. The authors also discuss real-life examples of virtual clinical trials and the potential barriers and challenges to implementing these modifications.

22. COVID-19 and beyond. Nat Cancer 2020; 1:568–572.

COVID-19 pandemic has resulted in the need to reassess the methodology of conventional cancer clinical trials to make them more pragmatic and patient-centric. In this article, the authors examine the various processes in a clinical trial and ways to adapt these processes to the virtual format.

23. Tan AC, Ashley DM, Khasraw M. Adapting to a pandemic – conducting oncology trials during the SARS-CoV-2 pandemic. Clin Cancer Res 2020; 26:3100–3103.

24. This paper reviews the challenges faced by investigators and sponsors in conducting clinical trials during the COVID-19 pandemic. The paper also describes the evolution of new practices in cancer clinical research, and how these can make clinical trials more cost-effective and feasible.

25. This review examines the role of virtual visits and digital approaches as an alternative to the in-person aspects of clinical research.

26. Sessa C, Cortes J, Conte P, et al. The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective. ESOMO Open 2022; 7:100359.

In this article, an international panel of oncology experts outline the impact of the pandemic on oncology clinical trials and propose potential solutions for clinical trial stakeholders.

27. Migliazzi J, Rodavitch A, Rieley G, et al. One committee to review it all: a single, multidisciplinary COVID-19 research committee. Contemp Clin Trials 2022; 117:106760.

28. van der Heijden MA, van der Putten RP, et al. “COVID-19 and the planning and conduct of oncology trials.” Cancer Treat Rev 2021; 53:101819.

29. “COVID-19: A Colombian Narrative.” Front Public Health 2022; 9:750755.

30. COVID-19 pandemic: the role of virtual visits and digital approaches. J Clin Transl Sci 2021; 5:103.

31. This review examines the role of virtual visits and digital approaches as an alternative to the in-person aspects of clinical research.

32. The impact of the COVID-19 pandemic on oncology care and clinical trials. Cancers 2021; 13:5924.